Cerebricon Ltd. : NaytaUutinen

Kuopio, Finland; London, UK: Cerebricon Ltd. Announces Exclusive License Agreement With University College London

February 9^th, 2009, Kuopio, Finland; London, UK
Cerebricon Ltd. Announces Exclusive License Agreement With University College London for Commercialization of a New Model of Attention Hyperactivity Disorder (ADHD) & States a Firm Intent to Provide Pertinent Models and Tools for Psychiatric Disorders.

Cerebricon Ltd. is proud to announce that it has completed negotiations with University College London (UCL) & UCL Business and has acquired an exclusive license in order to be able to breed and use the NK1R -/- mouse, which expresses all of the core features of ADHD, for 3^rd party testing of compounds aimed at combating and alleviating ADHD. Cerebricon will now make this model available to clientele as part of its service portfolio.

Dr Antti Nurmi, Cerebricon’s Head of CNS Models and Development, stated “We are pleased to have made this agreement with UCL Business and particularly pleased to have the opportunity to commercialize this model that was developed by Dr Stanford and Professor Hunt. We are also excited with the work of Professor Gurling and the linking of NK1 with ADHD in humans. Cerebricon already has a broad range of behavioral tests for psychiatry and with the inclusion of this model we will apply additional modalities such as microdialysis and our in-house MRI technologies. Models such as this, in conjunction with the advanced techniques that Cerebricon will apply to them, will serve as more powerful tools to facilitate therapies from the preclinical stage to the clinical stage in a quicker and more efficient fashion than has previously been seen.”

Dr Abbie Watts, UCL Business commented “In partnership with Cerebricon we think that our model of ADHD will become the gold standard for assessing the efficacy of new ADHD drugs. We know that ADHD is a complex pathology but we think we have found the best validated and best in class model of the disease.”

Dr Juha Yrjänheikki, CEO of Cerebricon commented “With the inclusion of this model to our current portfolio Cerebricon is signaling a firm intention to branch out toward models of psychiatry. We will continue to evaluate pertinent models of disease such as this model for ADHD that we have licensed exclusively from UCL and augment them with our in-house expertise.”

For more information please contact Cerebricon Ltd. info@cerebricon.com.

About ADHD:
ADHD is neurobehavioral developmental disorder that effects between 2-6% of school aged children globally. Treatment remains, in many cases, unsatisfactory and many pharmaceutical companies and academic groups are striving to provide better therapies and treatments for ADHD.

About Cerebricon Ltd.:
Cerebricon Ltd. is a collaborative and contract research organization, specializing in Preclinical models of CNS and PNS diseases for drug discovery and pharmacological research. Located in Kuopio, Finland with sales and marketing offices in London, UK and Los Angeles, USA. Cerebricon serves small, medium and large pharmaceutical companies as well as independent researchers and academic institutions around the globe. Cerebricon Ltd. is a completely privately owned company with fully proprietal staff and laboratories.

About UCL Business Plc.:
UCL Business PLC (UCLB) is the organisation responsible for commercialising research across all disciplines, generated from within UCL and associated organisations. It is primarily responsible for protecting inventions and transacting commercial activity including options, licences and collaborative commercial research. UCLB also has responsibility for creating and spinning-out companies from UCL.
UCLB is wholly-owned by UCL and operates as an independent company with its own Board of Directors.